A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. - Wikidata - wikimedia - TriplyDB

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.

http://www.wikidata.org/entity/Q34134986

about

New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding New investigational drugs with single-agent activity in multiple myeloma Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling Trial Watch: Proteasomal inhibitors for anticancer therapy Recent advances in antimultiple myeloma drug development.Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4 Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Proteasome inhibitors in cancer therapy Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.The 26S proteasome complex: an attractive target for cancer therapy Establishment of a human multiple myeloma xenograft model in the chicken to study tumor growth, invasion and angiogenesis.Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.From bortezomib to other inhibitors of the proteasome and beyond.The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.Novel proteasome inhibitors to overcome bortezomib resistance.Latest advances and current challenges in the treatment of multiple myeloma.New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies.Proteasome inhibitors in multiple myeloma: 10 years later.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.New proteasome inhibitors in myeloma.Mitosis-targeted anti-cancer therapies: where they stand.Sequential or combination therapy for multiple myeloma.Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.Proteasome inhibitors in acute leukemia.Synthesis and pharmacology of proteasome inhibitors.Experimental approaches in the treatment of multiple myeloma.Perspectives in the treatment of multiple myeloma.

P2860

Q26774372-BF32BF9E-747C-46D8-AFE9-E0ABA7A78D8C Q27677425-A2E82DA5-3392-4490-A729-C4F7D84BDBEC Q28071551-6F926A7D-CCBA-43B6-AFD8-930BF7DB8E46 Q28082335-BBCC3DB1-2D12-46B2-A2C4-FF2F47C4D49E Q28082910-4582BC25-8566-4D8F-AD36-A27EF987B267 Q33416297-C825AD65-3F81-4F97-B73E-739D4713EDA1 Q33675494-4FCC8DD2-7E85-4291-85D7-58FB9B38DA4B Q34020937-FAA03C74-122E-4698-BF28-23546F5646A0 Q34079481-D4A03C79-7B93-4E64-9102-854EEF34D46A Q34218976-F2A9F719-59FC-4041-A489-30C32FE78A9D Q34722352-D182C82B-F614-4A5D-A734-FEF982AA7D6E Q34773850-E0B09C70-F194-49E7-B16E-1064F24B37BC Q34788381-920BFBF3-40BD-41EA-BC3F-9EA3558E3720 Q34939959-F09526FF-1602-42F7-9766-894D56FA7151 Q35052044-AA7289E1-1419-48D2-B7AB-44EB542487D5 Q35624079-52C8E3BA-58CA-4961-804D-178985A4149E Q35636675-ED79A392-5BA4-4127-B975-B60C42C73C25 Q35764713-D9C9697B-2EB4-436C-AC10-F2C7904AA589 Q35824929-B23A73A5-321C-41B1-925F-7865820C317A Q35989980-A7D77626-5890-444E-9E74-68A0FD77DD27 Q36293871-D987795D-724C-4EA9-87A5-4FABFD38AC4D Q36709283-7D20D799-4F94-4DAC-8A19-7DB03B5B2BF3 Q36852277-74E42AD0-63E2-4EEF-B693-86B257D547A2 Q37132187-F47C8A79-DCA5-4C7F-A157-B829EBC1B7CE Q37166798-C2D3D4BA-1EB8-4468-ADEE-A2087BCCF3D3 Q37878771-0B5C4A25-A35F-40A2-BE44-ED1CF4C27AD7 Q37986287-199DF427-99C3-4AC1-90F3-29288C9066D6 Q38002469-244D316B-5640-412B-8587-F6A04A4A9615 Q38014395-0AC05C38-EAF0-4028-9BE0-03CE28596398 Q38019864-E967CE9F-8C97-45B0-9095-69E4A1A8544B Q38035044-E9DA0726-2C19-4A22-AA86-DDD65A72699E Q38037600-2FC4B4F3-B010-4D7F-B367-C69A35DEECF1 Q38052079-218AE2B9-985D-41B0-9D68-5902585B0FBA Q38053055-5629CF46-25B1-49B3-AB1B-A2C6B7ADDCA1 Q38059253-1075CF53-83EB-4FDE-961E-D1F445B1E467 Q38079578-3276E6D4-51E5-4B79-8ED8-5007A793827D Q38088003-5012284C-8FD6-45F0-902E-18CCA318E89F Q38092777-D1D649EF-8224-4F21-9D9F-4A29FFDA1266 Q38095958-A3B20A3E-B066-4F37-BD47-0939D18DE286 Q38108391-7A63820A-845E-42DD-92E2-A157EE5D66A1

P2860

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.

http://www.wikidata.org/entity/Q34134986

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A novel orally active proteaso ...... otoxicity in multiple myeloma.

@ast

A novel orally active proteaso ...... otoxicity in multiple myeloma.

@en

A novel orally active proteaso ...... otoxicity in multiple myeloma.

@nl

type

label

A novel orally active proteaso ...... otoxicity in multiple myeloma.

@ast

A novel orally active proteaso ...... otoxicity in multiple myeloma.

@en

A novel orally active proteaso ...... otoxicity in multiple myeloma.

@nl

prefLabel

A novel orally active proteaso ...... otoxicity in multiple myeloma.

@ast

A novel orally active proteaso ...... otoxicity in multiple myeloma.

@en

A novel orally active proteaso ...... otoxicity in multiple myeloma.

@nl

P1433

Q34134986-A24BA256-C22D-4CC8-95BD-CF3C798ADD87

P1476

Q34134986-662E47AA-A073-4312-8470-6D3B7E867005

P2093

Q34134986-0841FED9-6B3F-4F12-AC81-9405ABB53F60

Q34134986-3EAD5A46-8995-4747-80A2-F0A5AEEF9EFF

Q34134986-41B2D9A4-1218-47C7-A2F5-149004902E15

Q34134986-62B73182-68BE-4B6A-97B3-7131DBE466E5

Q34134986-84E25C36-64B2-4D76-BC0E-7B2B0C5044D1

Q34134986-91CA9374-356D-4D6F-8A50-F90C603AEFB4

Q34134986-A094E40A-CE45-41C4-9642-374709D5F9F2

P2860

Q34134986-05C04381-CCC2-4416-ACCB-CE2F63B58574

Q34134986-08B95202-ECF0-4FD3-A627-BD9FE28BFB7A

Q34134986-08E585BB-5C35-4C19-A518-6054164571EE

Q34134986-144D4DCC-31D9-42D7-A077-DF7D057D03EA

Q34134986-159CAB4D-3373-4ADD-9B2B-F8158EE49FA2

Q34134986-20220835-96B5-4BCB-B825-329C19E78247

Q34134986-23B6D2CA-B370-458E-8593-772E6A4C10CE

Q34134986-2FCEE982-96D0-475D-BE77-EFA92B13B696

Q34134986-32852C77-370A-4233-AC8E-B253F0B48940

Q34134986-3C337557-691D-4709-8B11-455FC98446DE

P304

Q34134986-C5B1ED4C-F7BF-41C1-A013-B10B952D7416

P31

Q34134986-9A239B02-9658-4F31-A725-DB421902F6A4

P356

Q34134986-6CB0FF1A-0B86-4395-AF0B-04F312936CAC

P407

Q34134986-9E9B4FDF-1FE5-4E4E-98ED-D3B29C0B6107

P433

Q34134986-031CC565-B5E1-41EF-B925-C5408170428E

P478

Q34134986-D4D48A30-D039-4446-8606-BA5C8331E35A

P50

Q34134986-88D042E9-1734-4454-B8AE-35053C8DFA45

Q34134986-9958A17D-0667-44CE-A6B5-526AD226E468

P577

Q34134986-C19139E1-B48B-4CD0-BE78-FADF411E8DB3

P5875

Q34134986-E2796CBB-DE07-4405-A078-FF62F8466C6F

P698

Q34134986-95EA3C92-D628-47A7-A482-CBDEE2B1C428

P921

Q34134986-25E78BA8-950E-49D6-80FF-26A92F561327

P932

Q34134986-44CBC764-B2E4-4311-B401-8CFBA5D063EC

P356

BLOOD-2010-04-276626

P1433

P1476

A novel orally active proteaso ...... otoxicity in multiple myeloma.

@en

P2093

Ajita V Singh

http://www.w3.org/2001/XMLSchema#string

Bryan Ciccarelli

http://www.w3.org/2001/XMLSchema#string

Christopher J Kirk

http://www.w3.org/2001/XMLSchema#string

Dharminder Chauhan

http://www.w3.org/2001/XMLSchema#string

Madhavi Bandi

http://www.w3.org/2001/XMLSchema#string

Monette Aujay

http://www.w3.org/2001/XMLSchema#string

Noopur Raje

http://www.w3.org/2001/XMLSchema#string

P2860

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase

Epoxomicin, a new antitumor agent of microbial origin

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

P304

4906-4915

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-04-276626

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2010-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46095318

http://www.w3.org/2001/XMLSchema#string

P698

20805366

http://www.w3.org/2001/XMLSchema#string

P921

P932

3321748

http://www.w3.org/2001/XMLSchema#string